Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.44 |
| ▸ | NAAA | Q02083 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.41 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14778639 | 1.00 | USP2 (0.47) | USP2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL20917644 | 1.00 | USP2 (0.47) | USP2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL738730 | 1.00 | USP2 (0.47) | USP2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL7539769 | 1.00 | USP2 (0.47) | USP2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL21247439 | 0.98 | USP2 (0.46) | USP2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL5570188 | 0.92 | KDM4E (0.45) | USP2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL28211898 | 0.88 | KDM4E (0.58) | USP2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL170853 | 0.88 | KDM4E (0.58) | USP2KDM4EDUSP3MEN1KMT2A | |
| SCHEMBL3483583 | 0.87 | KDM4E (0.58) | KDM4EDUSP3MEN1KMT2ALMNA | |
| SCHEMBL3483988 | 0.87 | KDM4E (0.58) | KDM4EDUSP3MEN1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1256336-B1 | Two-phase gel composition | PENRECO (US) | 2016-10-19 | — | — | EP | disclosed |
| US-9339446-B2 | Gel composition | CALUMET PENRECO, LLC (US) | 2016-05-17 | — | — | US | disclosed |
| US-20110045983-A1 | Gel composition | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2011-02-24 | — | — | US | disclosed |
| US-20090232753-A1 | Gel compositions | HEALY LIN LU | 2009-09-17 | — | — | US | disclosed |
| EP-1141111-B1 | GEL COMPOSITIONS | PENRECO (US) | 2005-08-03 | — | — | EP | disclosed |
| US-6881776-B2 | Gel compositions | PENRECO (US) | 2005-04-19 | — | — | US | disclosed |
| US-20050004274-A1 | Gel compositions | HEALY LIN LU (US) | 2005-01-06 | — | — | US | disclosed |
| EP-1256336-A2 | Two-phase gel composition | Penreco (US) | 2002-11-13 | — | — | EP | disclosed |
| US-20020055562-A1 | Gel compositions | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2002-05-09 | — | — | US | disclosed |
| EP-1141111-A1 | GEL COMPOSITIONS | Penreco (US) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000026285-A1 | GEL COMPOSITIONS | PENRECO (US) | 2000-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045983-A1 | Gel composition | PGR, COPE, PTGER1 | USP2 2278/4885KDM4E 584/4885DUSP3 4757/4885 |
| US-20090232753-A1 | Gel compositions | PGR, COPE, PTGER1 | USP2 2268/4885KDM4E 549/4885DUSP3 4758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.